Professional
Added to YB: 2025-12-22
Pitch date: 2025-10-13
NVO [neutral]
Novo Nordisk A/S
-24.91%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 350.87
Price Target
N/A
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
growth
Greenskeeper Asset Management Portfolio Holding: Novo Nordisk A/S
NVO (holding update): -19.6% after lowering guidance due to compounded GLP-1 competition, slow obesity market expansion, Lilly competition. New mgmt changes & efficiency focus. Expect compounding enforcement tailwinds, undervalued pipeline, obesity market expansion via broader indications, oral versions, better payer coverage.
Read full article (1 min)